S100A4 and pancreatic ductal adenocarcinoma: Moderate S100A4 overexpression was found in a doxorubicin-resistant colon cancer cell line compared to doxorubicin-sensitive cells (27), whereas S100A4 knockdown was associated with upregulation of BNIP3, increased sensitivity of pancreatic ductal adenocarcinoma cell lines to gemcitabine treatment, and enhanced apoptosis (28).